Johnson & Johnson has EU approval for nipocalimab for generalized myasthenia gravis, showing superior control and sustained benefits. Sanofi reported a safer protein COVID-19 vaccine versus...
Johnson & Johnson announced a new investment as part of its $55 billion US expansion, including a Montgomery County biomanufacturing site creating 500 permanent jobs and...
Johnson & Johnson’s Phase 3 MajesTEC-3 study shows that the combination of teclistamab and subcutaneous daratumumab (tec+dara) significantly improves outcomes for relapsed or refractory multiple myeloma...
Johnson & Johnson announces the acquisition of Shockwave Medical for $13.1 billion, expanding its presence in cardiovascular intervention. Subject to shareholder and regulatory approval, the deal...
Johnson & Johnson increased its sales by 1.3% in 2022, up to $95 billion, but reduces profits. Sales in the U.S. rose 2.9% to $12.5 billion...